Which has better valuation & earnings, TEM or WGS?

GeneDx has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempus AI $1.27B 10.31 -$245.03M -$1.44 N/A GeneDx $427.54M 6.07 -$21.02M -$3.64 N/A

Is TEM or WGS more profitable?

Tempus AI has a net margin of -17.77% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Tempus AI's return on equity. Company Net Margins Return on Equity Return on Assets Tempus AI -17.77% -50.28% -10.33% GeneDx -23.41% 4.12% 2.26%

Does the media prefer TEM or WGS?

In the previous week, Tempus AI had 45 more articles in the media than GeneDx. MarketBeat recorded 49 mentions for Tempus AI and 4 mentions for GeneDx. Tempus AI's average media sentiment score of 0.54 beat GeneDx's score of 0.51 indicating that Tempus AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempus AI 26 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation and earnings, HNGE or WGS?

GeneDx has lower revenue, but higher earnings than Hinge Health. GeneDx is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $587.86M 12.14 -$528.26M $1.28 69.09 GeneDx $427.54M 6.07 -$21.02M -$3.64 N/A

Is HNGE or WGS more profitable?

Hinge Health has a net margin of 15.15% compared to GeneDx's net margin of -23.41%. Hinge Health's return on equity of 51.60% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Hinge Health 15.15% 51.60% 14.16% GeneDx -23.41% 4.12% 2.26%

Does the media prefer HNGE or WGS?

In the previous week, Hinge Health had 6 more articles in the media than GeneDx. MarketBeat recorded 10 mentions for Hinge Health and 4 mentions for GeneDx. Hinge Health's average media sentiment score of 0.90 beat GeneDx's score of 0.51 indicating that Hinge Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hinge Health 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings and valuation, WGS or CHE?

Chemed has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 6.07 -$21.02M -$3.64 N/A Chemed $2.53B 2.80 $265.24M $19.91 27.19

Is WGS or CHE more profitable?

Chemed has a net margin of 10.60% compared to GeneDx's net margin of -23.41%. Chemed's return on equity of 31.77% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -23.41% 4.12% 2.26% Chemed 10.60% 31.77% 18.90%

Does the media refer more to WGS or CHE?

In the previous week, GeneDx and GeneDx both had 4 articles in the media. Chemed's average media sentiment score of 1.58 beat GeneDx's score of 0.51 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Chemed 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, WGS or HIMS?

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 6.07 -$21.02M -$3.64 N/A Hims & Hers Health $2.35B 3.35 $128.37M -$0.63 N/A

Does the media refer more to WGS or HIMS?

In the previous week, Hims & Hers Health had 38 more articles in the media than GeneDx. MarketBeat recorded 42 mentions for Hims & Hers Health and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.51 beat Hims & Hers Health's score of 0.22 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Hims & Hers Health 12 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, WGS or RDNT?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 6.07 -$21.02M -$3.64 N/A RadNet $2.04B 2.96 -$18.65M -$0.27 N/A

Is WGS or RDNT more profitable?

RadNet has a net margin of -0.93% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -23.41% 4.12% 2.26% RadNet -0.93% 2.61% 0.91%

Does the media refer more to WGS or RDNT?

In the previous week, RadNet had 1 more articles in the media than GeneDx. MarketBeat recorded 5 mentions for RadNet and 4 mentions for GeneDx. RadNet's average media sentiment score of 1.72 beat GeneDx's score of 0.51 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive RadNet 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

GeneDx (WGS) Competitors

$87.07 +4.52 (+5.48%)

As of 08/21/2026 04:00 PM Eastern

Compare

WGS vs. TEM, HNGE, CHE, HIMS, and RDNT

Should you buy GeneDx stock or one of its competitors? GeneDx's main competitors and comparable companies include Tempus AI (TEM), Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), and RadNet (RDNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does GeneDx compare to Tempus AI?

Tempus AI (NASDAQ:TEM) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Tempus AI has a net margin of -17.77% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Tempus AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempus AI	-17.77%	-50.28%	-10.33%
GeneDx	-23.41%	4.12%	2.26%

Tempus AI currently has a consensus target price of $65.69, suggesting a potential downside of 9.63%. GeneDx has a consensus target price of $89.57, suggesting a potential upside of 2.87%. Given GeneDx's stronger consensus rating and higher probable upside, analysts plainly believe GeneDx is more favorable than Tempus AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	2 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.41
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

GeneDx has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$1.27B	10.31	-$245.03M	-$1.44	N/A
GeneDx	$427.54M	6.07	-$21.02M	-$3.64	N/A

24.2% of Tempus AI shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 24.3% of Tempus AI shares are held by company insiders. Comparatively, 25.2% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tempus AI has a beta of 3.58, indicating that its share price is 258% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

In the previous week, Tempus AI had 45 more articles in the media than GeneDx. MarketBeat recorded 49 mentions for Tempus AI and 4 mentions for GeneDx. Tempus AI's average media sentiment score of 0.54 beat GeneDx's score of 0.51 indicating that Tempus AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempus AI	26 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Tempus AI and GeneDx tied by winning 8 of the 16 factors compared between the two stocks.

How does GeneDx compare to Hinge Health?

Hinge Health (NYSE:HNGE) and GeneDx (NASDAQ:WGS) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Hinge Health has a net margin of 15.15% compared to GeneDx's net margin of -23.41%. Hinge Health's return on equity of 51.60% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hinge Health	15.15%	51.60%	14.16%
GeneDx	-23.41%	4.12%	2.26%

61.7% of GeneDx shares are held by institutional investors. 18.9% of Hinge Health shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

GeneDx has lower revenue, but higher earnings than Hinge Health. GeneDx is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hinge Health	$587.86M	12.14	-$528.26M	$1.28	69.09
GeneDx	$427.54M	6.07	-$21.02M	-$3.64	N/A

Hinge Health has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Hinge Health currently has a consensus target price of $100.57, suggesting a potential upside of 13.72%. GeneDx has a consensus target price of $89.57, suggesting a potential upside of 2.87%. Given Hinge Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Hinge Health is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Hinge Health had 6 more articles in the media than GeneDx. MarketBeat recorded 10 mentions for Hinge Health and 4 mentions for GeneDx. Hinge Health's average media sentiment score of 0.90 beat GeneDx's score of 0.51 indicating that Hinge Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hinge Health	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Hinge Health beats GeneDx on 13 of the 17 factors compared between the two stocks.

How does GeneDx compare to Chemed?

GeneDx (NASDAQ:WGS) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Chemed has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	6.07	-$21.02M	-$3.64	N/A
Chemed	$2.53B	2.80	$265.24M	$19.91	27.19

In the previous week, GeneDx and GeneDx both had 4 articles in the media. Chemed's average media sentiment score of 1.58 beat GeneDx's score of 0.51 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Chemed	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

GeneDx has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Chemed has a net margin of 10.60% compared to GeneDx's net margin of -23.41%. Chemed's return on equity of 31.77% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Chemed	10.60%	31.77%	18.90%

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 25.2% of GeneDx shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

GeneDx presently has a consensus price target of $89.57, indicating a potential upside of 2.87%. Chemed has a consensus price target of $530.75, indicating a potential downside of 1.95%. Given GeneDx's stronger consensus rating and higher possible upside, equities research analysts plainly believe GeneDx is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Chemed beats GeneDx on 9 of the 15 factors compared between the two stocks.

How does GeneDx compare to Hims & Hers Health?

GeneDx (NASDAQ:WGS) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

GeneDx has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than GeneDx. Hims & Hers Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	6.07	-$21.02M	-$3.64	N/A
Hims & Hers Health	$2.35B	3.35	$128.37M	-$0.63	N/A

In the previous week, Hims & Hers Health had 38 more articles in the media than GeneDx. MarketBeat recorded 42 mentions for Hims & Hers Health and 4 mentions for GeneDx. GeneDx's average media sentiment score of 0.51 beat Hims & Hers Health's score of 0.22 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Hims & Hers Health	12 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeneDx presently has a consensus target price of $89.57, indicating a potential upside of 2.87%. Hims & Hers Health has a consensus target price of $32.17, indicating a potential downside of 4.46%. Given GeneDx's stronger consensus rating and higher probable upside, equities research analysts plainly believe GeneDx is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Hims & Hers Health has a net margin of -5.51% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

61.7% of GeneDx shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

GeneDx beats Hims & Hers Health on 9 of the 16 factors compared between the two stocks.

How does GeneDx compare to RadNet?

GeneDx (NASDAQ:WGS) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, RadNet had 1 more articles in the media than GeneDx. MarketBeat recorded 5 mentions for RadNet and 4 mentions for GeneDx. RadNet's average media sentiment score of 1.72 beat GeneDx's score of 0.51 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
RadNet	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

GeneDx currently has a consensus target price of $89.57, suggesting a potential upside of 2.87%. RadNet has a consensus target price of $88.00, suggesting a potential upside of 14.55%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	6.07	-$21.02M	-$3.64	N/A
RadNet	$2.04B	2.96	-$18.65M	-$0.27	N/A

61.7% of GeneDx shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

RadNet has a net margin of -0.93% compared to GeneDx's net margin of -23.41%. GeneDx's return on equity of 4.12% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-23.41%	4.12%	2.26%
RadNet	-0.93%	2.61%	0.91%

GeneDx has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, RadNet has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Summary

RadNet beats GeneDx on 10 of the 17 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.60B	$9.83B	$7.37B	$12.85B
Dividend Yield	N/A	2.55%	2.54%	11.08%
P/E Ratio	-23.92	34.38	272.88	24.24
Price / Sales	6.07	4.97	618.96	99.76
Price / Cash	37.98	125.12	78.62	53.99
Price / Book	10.63	4.05	13.05	6.20
Net Income	-$21.02M	$311.06M	$3.47B	$348.59M
7 Day Performance	11.51%	0.83%	2.09%	0.08%
1 Month Performance	37.38%	2.42%	6.64%	3.88%
1 Year Performance	-32.33%	15.69%	25.02%	16.98%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	2.1159 of 5 stars	$87.07 +5.5%	$89.57 +2.9%	-32.3%	$2.60B	$427.54M	N/A	1,300
TEM Tempus AI	1.5766 of 5 stars	$61.25 +24.1%	$65.69 +7.3%	-9.7%	$8.91B	$1.27B	N/A	3,800	Trending News Analyst Forecast Insider Trade Options Volume High Trading Volume
HNGE Hinge Health	3.7351 of 5 stars	$88.47 +0.3%	$100.57 +13.7%	+53.9%	$7.12B	$587.86M	69.12	1,437	Insider Trade
CHE Chemed	4.0452 of 5 stars	$535.86 +1.3%	$530.75 -1.0%	+17.7%	$6.92B	$2.53B	26.91	15,811	Positive News
HIMS Hims & Hers Health	1.8522 of 5 stars	$31.03 +13.3%	$32.43 +4.5%	-24.4%	$6.39B	$2.35B	N/A	2,442	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors